Therapy de‐escalation in pediatric patients with inflammatory bowel disease in remission: Data analysis from the CEDATA registry
Journal of Pediatric Gastroenterology and Nutrition · 2025
DOI: 10.1002/jpn3.70297 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, 2025. Verfasst von Sila Cekin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Crohn Disease, Inflammatory Bowel Diseases, Tumor Necrosis Factor Inhibitors. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GPGE e.V., the Pediatric Gastroenterology, Hepatology and Nutrition Society in German-speaking countries.
Abstract (Originalsprache)
Objectives
There are no standardized criteria about stepping down from combination therapy (immunomodulator and tumor necrosis factor (TNF)‐alpha‐inhibitors) in children with inflammatory bowel disease (IBD) to reduce risk for side effects. Our aim was to describe how de‐escalation has been performed in a large pediatric cohort and to find prognostic factors for therapy de‐escalation without the need for therapy adjustments post‐de‐escalation.
Methods
Real‐world data from CEDATA‐GPGE, a German‐Austrian registry for pediatric IBD patients, from 2004 to 2023, were analyzed. Patients not requiring therapy adjustments post‐de‐escalation and patients requiring therapy adjustments after de‐escalation were compared, and prognostic factors were identified.
Results
Two hundred and thirty out of 6248 registered patients received combination therapy for at least 6 months. In 64 patients therapy adjustment was not required after de‐escalation. Crohn's disease (CD) patients, younger patients, and patients with positive modified predictors of poor outcome were significantly more often on combination therapy. Regarding de‐escalation, CD patients were more often successfully de‐escalated than ulcerative colitis (UC) and IBD‐unclassified patients. UC patients with a less severe disease manifestation (Paris classification E1 or E2) were de‐escalated more successfully than those with more extensive disease (E3 or E4). De‐escalation to monotherapy with a biologic led to a more successful de‐escalation than de‐escalation to immunomodulator monotherapy or stopping both biologic and immunomodulator.
Conclusions
De‐escalation is more likely successful in patients with CD, and de‐escalating combination therapy to monotherapy with a TNF‐alpha‐inhibitor is more advantageous.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Paediatrics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
- Department of General Paediatrics and Neonatology, Pediatric Gastroenterology, University of Giessen, Giessen, Germany.
ORCID-Profile: Sila Cekin
Förderung
- GPGE e.V., the Pediatric Gastroenterology, Hepatology and Nutrition Society in German-speaking countries
Zitieren
APA
Cekin, S., Huenseler, C., Cantez, S., Broekaert, I., de Laffolie, J., & CEDATA‐GPGE® Study Group (2025). Therapy de‐escalation in pediatric patients with inflammatory bowel disease in remission: Data analysis from the CEDATA registry. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.70297
Vancouver
Cekin S, Huenseler C, Cantez S, Broekaert I, de Laffolie J, CEDATA‐GPGE® Study Group. Therapy de‐escalation in pediatric patients with inflammatory bowel disease in remission: Data analysis from the CEDATA registry. Journal of Pediatric Gastroenterology and Nutrition. 2025. doi:10.1002/jpn3.70297
BibTeX
@article{Cekin2025,
author = {Cekin, Sila and Huenseler, Christoph and Cantez, Serdar and Broekaert, Ilse and de Laffolie, Jan and CEDATA‐GPGE® Study Group, CEDATA‐GPGE® Study Group},
title = {Therapy de‐escalation in pediatric patients with inflammatory bowel disease in remission: Data analysis from the CEDATA registry},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2025},
doi = {10.1002/jpn3.70297}
}
EUVIMED